195 related articles for article (PubMed ID: 28337384)
1. Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?
Li F; Ling X; Harris DL; Liao J; Wang Y; Westover D; Jiang G; Xu B; Boland PM; Jin C
Am J Cancer Res; 2017; 7(2):370-382. PubMed ID: 28337384
[TBL] [Abstract][Full Text] [Related]
2. FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models.
Ling X; Liu X; Zhong K; Smith N; Prey J; Li F
Am J Transl Res; 2015; 7(10):1765-81. PubMed ID: 26692923
[TBL] [Abstract][Full Text] [Related]
3. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
Li F; Jiang T; Li Q; Ling X
Am J Cancer Res; 2017; 7(12):2350-2394. PubMed ID: 29312794
[TBL] [Abstract][Full Text] [Related]
4. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.
Ling X; Cao S; Cheng Q; Keefe JT; Rustum YM; Li F
PLoS One; 2012; 7(9):e45571. PubMed ID: 23029106
[TBL] [Abstract][Full Text] [Related]
5. Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?
Li F
Am J Cancer Res; 2014; 4(3):304-11. PubMed ID: 24959385
[TBL] [Abstract][Full Text] [Related]
6. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
[TBL] [Abstract][Full Text] [Related]
7. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX.
Ling X; Xu C; Fan C; Zhong K; Li F; Wang X
Cancer Res; 2014 Dec; 74(24):7487-97. PubMed ID: 25512388
[TBL] [Abstract][Full Text] [Related]
8. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.
Ling X; Wu W; Fan C; Xu C; Liao J; Rich LJ; Huang RY; Repasky EA; Wang X; Li F
J Exp Clin Cancer Res; 2018 Oct; 37(1):240. PubMed ID: 30285798
[TBL] [Abstract][Full Text] [Related]
9. Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX.
Thangaiyan R; Aljahdali IA; Lent-Moore KY; Liao J; Ling X; Li F
Am J Transl Res; 2021; 13(7):7458-7474. PubMed ID: 34377229
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration.
Zhao J; Ling X; Cao S; Liu X; Wan S; Jiang T; Li F
Mol Pharm; 2014 Feb; 11(2):457-67. PubMed ID: 24329001
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and In Vitro/In Vivo Anti-Cancer Activities of Novel (20
Dai X; Wu G; Zhang Y; Zhang X; Yin R; Qi X; Li J; Jiang T
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187360
[TBL] [Abstract][Full Text] [Related]
12. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of novel 10,11-methylenedioxy-camptothecin glycoside derivatives and investigation of their anti-tumor effects
Wu G; Mai X; Liu F; Lin M; Dong X; Xu Q; Hao C; Zhang L; Yu R; Jiang T
RSC Adv; 2019 Apr; 9(20):11142-11150. PubMed ID: 35520228
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to topoisomerase I-targeting drugs.
Rasheed ZA; Rubin EH
Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
[TBL] [Abstract][Full Text] [Related]
15. An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI).
Ling X; Li F
Am J Transl Res; 2013; 5(2):139-54. PubMed ID: 23573360
[TBL] [Abstract][Full Text] [Related]
16. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
[TBL] [Abstract][Full Text] [Related]
17. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
Zhang G; Yin R; Dai X; Wu G; Qi X; Yu R; Li J; Jiang T
Eur J Med Chem; 2022 Nov; 241():114610. PubMed ID: 35932565
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
